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Abstract
Background: We have previously identified genome-wide DNA methylation changes in a cell line model of breast cancer
metastasis. These complex epigenetic changes that we observed, along with concurrent karyotype analyses, have led us to
hypothesize that complex genomic alterations in cancer cells (deletions, translocations and ploidy) are superimposed over
promoter-specific methylation events that are responsible for gene-specific expression changes observed in breast cancer
metastasis.
Methodology/Principal Findings: We undertook simultaneous high-resolution, whole-genome analyses of MDA-MB-
468GFP and MDA-MB-468GFP-LN human breast cancer cell lines (an isogenic, paired lymphatic metastasis cell line model)
using Affymetrix gene expression (U133), promoter (1.0R), and SNP/CNV (SNP 6.0) microarray platforms to correlate data
from gene expression, epigenetic (DNA methylation), and combination copy number variant/single nucleotide
polymorphism microarrays. Using Partek Software and Ingenuity Pathway Analysis we integrated datasets from these
three platforms and detected multiple hypomethylation and hypermethylation events. Many of these epigenetic alterations
correlated with gene expression changes. In addition, gene dosage events correlated with the karyotypic differences
observed between the cell lines and were reflected in specific promoter methylation patterns. Gene subsets were identified
that correlated hyper (and hypo) methylation with the loss (or gain) of gene expression and in parallel, with gene dosage
losses and gains, respectively. Individual gene targets from these subsets were also validated for their methylation,
expression and copy number status, and susceptible gene pathways were identified that may indicate how selective
advantage drives the processes of tumourigenesis and metastasis.
Conclusions/Significance: Our approach allows more precisely profiling of functionally relevant epigenetic signatures that
are associated with cancer progression and metastasis.
Citation: Andrews J, Kennette W, Pilon J, Hodgson A, Tuck AB, et al. (2010) Multi-Platform Whole-Genome Microarray Analyses Refine the Epigenetic Signature of
Breast Cancer Metastasis with Gene Expression and Copy Number. PLoS ONE 5(1): e8665. doi:10.1371/journal.pone.0008665
Editor: Syed A. Aziz, Health Canada, Canada
Received October 15, 2009; Accepted November 6, 2009; Published January 13, 2010
Copyright:  2010 Andrews et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Financial support gratefully acknowledged by grant #016506 from the Canadian Breast Cancer Research Alliance, with special funding support from
the Canadian Breast Cancer Foundation and the Cancer Research Society. AFC is Canada Research Chair in Oncology, supported by the Canada Research Chairs
Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: drodenhi@uwo.ca
Introduction
A variety of whole-genome approaches have been used to
identify the molecular profiles that contribute to and reflect cancer
progression. To date, the scope of such whole genome profiling
efforts has encompassed classical karyotypic analyses that identify
chromosomal rearrangements [1], as well as gene expression
profile [2] and epigenetic studies (including by our group; [3,4])
that provide snap-shot signatures of gene expression and
chromatin modification patterns, respectively. In the context of
breast cancer, whole genome approaches have identified prog-
nostic gene sets that predict a short interval to distant metastases
(i.e. a poor prognosis signature; [5,6,7]) and described gene profiles
that mediate metastasis to a secondary site [8,9,10]. However, few
reports have identified epigenetic signatures of breast cancer,
particularly in the context of epigenetic mechanisms of tumour-
igenesis that could be applied in cancer management. Such
applications could provide diagnostic tests, prognostic factors and
predictors of treatment response that would complement standard
gene-expression based assays [11]. Furthermore, the integration of
data sets from multiple whole genome platforms is complicated by
the interrelated nature of the genetic and epigenetic signatures that
characterize individual cells in both their normal or tumourigenic
states [12]. For example, gene expression can be regulated at
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methylation or through histone modifications that modify
chromatin accessibility. In addition, recent reports show that gene
copy number adds a further level of complexity in understanding
the molecular context of health and disease states. This is because
variations in gene dosage can complicate the interpretation of
microarray data and may also differentially contribute to the
developmental or tumour phenotype [13]. In only a few reports
have such whole genome profiling efforts been integrated [14,15],
allowing a multi-dimensional characterization of biological systems
[16]. In perhaps the most thorough report to date, integrative
analysis of global cancer-related changes in DNA methylation,
genomic imbalance, and gene expression provided evidence of the
cumulative roles of epigenetic and genetic mechanisms in
deregulation of gene expression networks in osteosarcoma [17],
providing evidence for the combined contributions of genetic,
epigenetic and chromosomal (cytogenetic) alterations to tumour
progression.
Previously, we described the first use of a human gene promoter
tiling microarray platform to identify genome-wide DNA meth-
ylation patterns in a human breast cancer cell line model of
metastasis [4]. Gene networks and pathways were identified in
MDA-MB-468GFP (468GFP) and MDA-MB-468LN (468LN)
cells and selected target genes associated with epithelial–mesen-
chymal transition (EMT) were validated with respect to DNA
methylation effects on gene expression. Although we found that
many hypermethylation and hypomethylation events were inter-
spersed across the genome, we also observed an apparent
clustering of methylation events within identifiable chromosomal
regions. For example, enriched regions of hypermethylation events
were identified on chromosomes 6p, 7p, 11p/q, 18p and 19p/q,
and similar clustering of hypomethylated events (on 1p, 3q, 7q and
20q) was also found [3,4]. Analyses were subsequently undertaken
that identified complex chromosomal rearrangements, including
deletions, translocations and ploidy differences between these cell
lines [1]. We also observed that a number of these chromosomal
rearrangements included regions to which we had assigned
clustered methylation signatures in our promoter methylation
profiling study. Thus, these complementary data sets generated by
our two studies have led us to hypothesize that complex genomic
alterations in cancer cells (deletions, translocations and ploidy) are
superimposed over promoter-specific methylation events respon-
sible for gene-specific expression changes in breast cancer
metastasis.
Here we tested this hypothesis using whole-genome platforms to
cross reference gene expression, epigenetic and copy number data,
in this human model of breast cancer metastasis [18]. Briefly, we
undertook simultaneous high-resolution, whole-genome analyses
using Affymetrix gene expression (U133) promoter (1.0R) and
Copy Number Variation/Single Nucleotide Polymorphism (SNP
6.0) microarray platforms to correlate gene expression, epigenetic
(DNA methylation), and gene copy number information. We
observed widespread hypomethylation and hypermethylation
differences within this cell line pair, many of which (,650)
correlate with gene expression changes. In addition, gene dosage
events correlated with the profound karyotypic differences
between the cell lines and were reflected in the methylation
patterns that we observed. We used Partek Software analyses to
integrate the three microarray platforms and to identify subsets of
genes with methylation/expression patterns that were either
dependent (or independent) of gene copy number. These included
the SFN, TMEM16A, WNT5A, DLC1 and HOXD13 genes, the
expression of which were validated by Quantitative Real Time
PCR (qRT-PCR). Our integrated report thus provides an
algorithm to logically assess prospective gene targets that are
epigenetically regulated and those that are altered by copy number
(but are not epigenetically modified) thus allowing us to refine the
epigenetic signatures of breast cancer.
Materials and Methods
Cell Culture and Genomic DNA (gDNA)/Total RNA
Extraction
MDA-MB-468GFP (468GFP) and MDA-MB-468GFP-LN
(468LN) human breast cancer cell lines were isolated and
characterised as described previously [18]. For gene expression
studies, cells were grown from frozen stocks in aMEM medium
(Invitrogen) Supplemented with 10% FCS (Wisent Inc.) for 4
passages, without the use of antibiotics. At the fifth passage, each
cell line was split into parallel flasks (three each for expression and
promoter analysis, and two for Copy Number Variation/Single
Nucleotide Polymorphism (CNV/SNP) analysis, and grown to
approximately 70% confluence. In some experiments, 468LN cells
were cultured (with antibiotics) for 72 hours in the presence of
10 mM 5-aza-29-deoxycytidine (5-azaC), with or without an
additional 16 hour exposure to the histone deacetylase inhibitor
Trichostatin A (TSA; 50 nM). A fourth treatment group with 5-
azaC for 88 hours was also added. For gene expression
microarrays, total RNA from each biological replicate was isolated
using Trizol (Invitrogen) as per the manufacturer’s instructions.
For CNV/SNP arrays, genomic DNA (gDNA) was isolated from
each flask separately using the GenElute Genomic DNA Miniprep
kit (Sigma-Aldrich, St. Louis, MO, USA), as per the manufactur-
er’s instructions. All microarray hybridizations, staining, washing,
scanning, and data analyses were carried out at the London
Regional Genomics Centre [47]. A complete list of PCR primers
used in this study is presented in Table S1.
Gene Expression Microarrays
Total RNA from each biological replicate was isolated using
Trizol (Invitrogen) as per the manufacturer’s instructions. 10
micrograms of RNA was used to produce Biotin-labeled cRNA,
which was hybridized to Affymetrix HGU133_Plus_2 arrays.
Array washing, scanning and probe quantification were carried
out as per the manufacturer’s instructions using GCOS software
[48], except that the target intensity was set to 150. For each array,
GCOS output was imported as. CEL files into Partek Genomic
Suite software (Agilent), and data were normalized using the RMA
(Robust Multichip Averaging) algorithm. ANOVA with nominal
alpha value set to 0.05 was then used to determine those probe sets
significantly different between the 468GFP and 468LN cell lines,
followed by a Benjamini and Hochberg Multiple testing correction
to reduce the false positive rate. These results were then separated
by significant increasers or decreasers, and used in cross platform
analysis.
Human Promoter Microarrays
Analysis of hyper- and hypomethylated promoters in 468GFP vs
468LN was carried out using Affymetrix Human Promoter 1.0R
arrays as described previously [4]. The annotations for the
HGU133_Plus_2 array were used to determine which probe sets
were associated with regions appearing to be significantly hyper-
or hypomethylated in 468LN vs 468GFP cells, and these probe set
IDs were used in cross platform analyses.
CNV/SNP Microarray Analysis
To detect copy number variations in the 468LN vs the 468GFP
cell lines, 4 mg of the same genomic DNA used in promoter
Epigenetics and Metastasis
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SNP 6.0 arrays. This array contains probes used in SNP analysis,
as well as probes specific for CNV detection. CEL files produced
by GCOS software for each array were then imported into Partek
Genomic Suite and analyzed using the Copy Number Analysis
workflow. All. CEL files were background corrected using RMA as
above, and results were corrected for probe GC content and
fragment length. 468LN cells were compared directly to 468GFP
cells. Significantly different regions were determined using the
Hidden Markov Model algorithm of the Partek Genomic Suite set
to detect copy number (CN) states of 0.1, 1, 3, 4, 5 (a CN state of 2
was ignored), with the minimum number of probe sets contained
in a region for it to be considered set to 3. Only regions of CNV
showing up in two of two replicates were reported, and both SNP
and CNV probes were used in the analysis. Regions identified
were annotated with gene symbols by importing the annotation file
from the UCSC genome browser (build hg18). Affymetrix Probe
IDs from the HGU133_ Plus_2 array for the genes in all regions
appearing either increased or decreased in copy number in the
468LN/468GFP direct comparison were obtained by submitting
the gene symbols to Affymetrix through the Netaffx tool [49];
(http://www.affymetrix.com/analysis/index.affx). Alternatively,
468GFP or 468LN samples were compared to samples taken
from normal females. As a normal reference population, we used a
subset of 60 Yoruba (YRI; Ibidan, Nigeria) females of the 270
samples from the International HapMap project, which were run
on the SNP 6.0 array (data available at Affymetrix). The
microarray data discussed in this publication have been deposited
in the National Center for Biotechnology Information’s Gene
Expression Omnibus (GEO) under accession GSE15619, along
with detailed protocol notes.
Cross Platform Venn Analysis
Probe set IDs from each of the three Microarray platforms were
imported as separate lists into Genespring 7.3 GX (Agilent), and
compared using the Venn Analysis tool. Probe sets appearing
hypomethylated, increased in expression, and increased in copy
number were compared in one analysis, and probe sets appearing
hypermethylated, decreased in expression, and decreased in copy
number in another. Lists of overlapping probe sets were then
generated, and filtered in EXCEL to determine the number of
unique genes represented. Proportionate Venn diagrams were
then created based on these data sets.
Bisulfite Genomic Sequencing
Hyper- or hypomethylation of regions predicted from the array
analysis were confirmed using a variation of the bisulfite
conversion method [19]. Genomic DNA (gDNA; 2 mg) was
bisulfite treated using the Epitect DNA bisulfite treatment kit
(Qiagen) as per the manufacturer’s instructions. Primers specific to
the converted gDNA were designed using the MethPrimer
software [20] with the default parameters, except that amplicons
were designed to be between 200 and 500 base pairs. For each cell
line, 60 ng of each converted gDNA was subjected to PCR in 1X
buffer, 200 uM dNTPs, 2.0–2.5 mM MgCl2, 400 nM forward
and reverse primers (Sigma-Genosys), and 1 Unit Taq Polymerase
(Invitrogen). The cycling conditions used were 1 cycle of 94uC for
5 minutes, followed by 5 cycles of 94uC for 1 minute, 55uC for 2
minutes, and 72uC for 2.5 minutes. This was followed by 35 cycles
of 94uC for 1 minute, 55uC for 1 minute, and 72uC for 1.5
minutes. PCR products were visualized using agarose gel
electrophoresis/ethidium bromide staining, and PCR products
purified using the Qiaquick PCR purification kit. For each CpG
island to be tested, 25 ng of purified PCR products from each cell
line were then ligated into the T-vector PCR2.1 (Invitrogen)
overnight at 14uC as per the manufacturer’s instructions. Plasmids
thus generated were transformed into TOP10 competent bacteria
using the heat shock method and transformed bacteria were
spread onto LB-Agar plates containing 100 mg/mL ampicillin, and
50 mL of 10 mg/mL 5-bromo-4-chloro-3-indolyl-beta-D-galacto-
pyranoside (X-gal). Plates were incubated overnight at 37uC, and
white colonies were picked and ‘‘patched’’ onto fresh LB-Agar
plates. Potential clones were directly screened by PCR using gene
specific primers, and clones showing the expected band size were
inoculated into 2 mL of TB containing 100 mg/mL ampicillin and
grown overnight at 37uC. Plasmid DNA was isolated using the
Genelute Plasmid Miniprep kit (Sigma), and sequenced using the
T7 promoter primer. Clone sequences thus obtained were
compared to the expected sequence using the ClustalW alignment
algorithm [21].
Quantitative Real Time PCR (qRT-PCR)
qRT-PCR was used to confirm the effect of promoter
methylation on gene expression. For each cell line, RNA used
for expression microarray analysis was also used to synthesize
cDNA with Superscript II (Invitrogen), as per the manufacturer’s
instructions. Real-time primers were then designed for each gene
using Primerquest Software (Integrated DNA Technologies, [50])
with 18S chosen as the reference gene. Reactions (in triplicate for
each biological replicate) used RT
2 qPCR Mastermix (SABios-
ciences, Frederick, MD, USA), 200 nM forward and reverse
primers, 200 uM dNTPs, and 1 uL cDNA diluted 1:5 or 1:10,
using the Rotorgene RG-3000 thermocycler (Corbett Research,
Kirkland, PQ, Canada). Standard curves were generated for each
gene, using cDNA derived from a serial 3 fold dilution of cDNA
derived from one of the biological replicates. cDNA from 468GFP
cells was used for the standard curves, where the gene was
expected to be increased in its expression in this line relative to
468LN; otherwise cDNA from the 468LN cell line was used. For
each biological replicate, relative amounts of each gene were
determined by comparison to the standard curve. The ‘‘unknown’’
samples were then normalized to 18S, and the expression level in
the parental 468GFP cell line was set to 1. Results are presented as
fold change relative to control. A similar method was used to
examine the change in expression of SFN, TMEM16A and
WNT5A in 468LN cells after treatment with 5-azaC, with or
without TSA, except that GAPDH was used as the internal control
gene.
qRT-PCR was also used to confirm copy number. Exonprimer
software [51] was used to design primers that amplify across an
exon for each gene of interest. The human mispriming library was
used to decrease the probability of cross hybridization of primers.
Standard curves for each primer set were generated using serial 5
fold dilutions of normal human female DNA (Novagen), starting at
30 ng/mL. qRT-PCR was carried out as above, except that 15 ng
per reaction of the same genomic DNA used in the promoter array
analysis was used. For each biological replicate, relative amounts
of each gene were determined by comparison to the standard
curve. The ‘‘unknown’’ samples were then normalized to b-globin,
and the copy number in the parental 468GFP cell line was set to 1.
Results are presented as fold change relative to control 6 SEM. P-
values were calculated by first log (base10) transforming the
individual normalized ratios, and the normal distribution of each
group (468GFP or 468LN) was checked using the Kolmogorov-
Smirnov test. Equality of Variances was checked and confirmed
using Levene’s test, and p-values for copy number change in
468LN relative to 468GFP was calculated using the students t-test.
Epigenetics and Metastasis
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(Systat Software, Point Richmond, CA, USA).
Ingenuity Pathway Analysis (IPA)
Gene networks and canonical pathways representing key
genes were identified using the curated Ingenuity Pathways
Analysis (IPA) database as previously described [4]. Briefly, the
data set containing gene identifiers and corresponding fold
changes was uploaded into the web-delivered application and
each gene identifier was mapped to its corresponding gene
object in the Ingenuity Pathways Knowledge Base (IPKB). The
functional analysis identified the biological functions and/or
diseases that were most significant to the data sets. Fisher’s exact
test was performed to calculate a p value determining the
probability that each biological function and/or disease assigned
to the data set was due to chance alone. The data set was mined
for significant pathways with the IPA library of canonical
pathways and networks were generated by using IPA as
graphical representations of the molecular relationships between
genes and gene products. The intensity of genes (node) colour in
the networks indicates the degree of downregulation (green) or
upregulation (red) of gene expression. Nodes are displayed using
various shapes that represent the functional class of gene
products.
Results
Copy Number Analyses Reveal Chromosomal Gains and
Losses in These Breast Cancer Cell Lines
We undertook high-resolution whole genome profiling using
several Affymetrix microarray platforms to cross reference gene
dosage, expression and DNA methylation changes in an isogenic,
paired cell lines based on the human MDA-MB-468 breast
adenocarcinoma cell line [18,22,23]. The cell lines used in the
present study include the GFP-transfected parental, poorly
metastatic MDA-MB-468GFP (468GFP) cell line and a progeny
MDA-MB-468GFP-LN (468LN) cell line variant that is highly
tumourigenic and that also maintains a propensity to metastasize
in a mouse xenograft models. Previously, we had used classical
karyotype analyses to identify complex chromosomal rearrange-
ments that were both shared and unique to each of the two cell
lines [1]. Although karyotyping identifies genetically distinct cell
clones within a cancer cell population, it is difficult to cross
reference karyotype data with data from other whole genome
platforms. Therefore, the Affymetrix genome-wide SNP array 6.0
platform was used to provide copy number estimates across the
genomes of the 468GFP and 468LN cells. (All copy number
microarray data are presented in Tables S2 and S3.) There are
more than 1.8 million markers on a single 6.0 array, with half of
these being non-polymorphic probes selected for their linear
response to copy number and genomic position [24]. Two arrays
were probed with duplicate DNA samples from the 468GFP and
the 468LN cell lines, with the resultant data imported into and
analyzed with the Partek Genomic Suite (Figure 1). When data
were mapped to individual chromosomes, we were able to identify
approximately 96 large regions of chromosome copy number
differences between the 468LN and the 468GFP cells, spanning
from 10–100 megabases (Figure 2). A number of these
chromosomal changes appeared to reflect the common aberrations
we had previously reported by karyotype analysis [1].
These regional changes in chromosome copy number were
particularly obvious when heat maps generated from 468GFP and
468LN DNAs were compared to a normal reference female
Yoruba (YRI) population (Ibadan, Nigeria; [25]) from the
International HapMap Project (Figure 3). This particular
comparator population was chosen because the MDA-MB-468
cell line was originally isolated from the pleural effusion of a 51-
year-old African-American female patient with metastatic adeno-
carcinoma of the breast [22]. As shown in Figure 3, comparisons
of probe heat maps from these three genomes (468GFP, 468LN
and YRI) showed complex differences among all three genomes.
The 468LN genome possessed regions that appeared unchanged
from the control population but also displayed regions that differed
between 468GFP and 468LN cells. In comparing the 468LN vs
468GFP genomes (Table 1), the median copy number increase
was 3.84N (range 2.11 – 47.50), with a median size of an amplified
region being 666 kb (range 8 bp–36 Mb), while the median copy
number decrease was 1.23N (range 0.07 – 1.92), with a median
size of deleted region of 292 kb (range 6 bp–31 Mb). Copy
number (averaged across the chromosomal regions; hence the
fractional values) and fragment size data specific to each
chromosome are also provided in Table 1. Specific examples of
these regional changes in copy number can also be observed in the
representative context of chromosome 6, by comparing the data
across the three genomes (Figure 4). Genome comparisons
between 468LN vs 468GFP revealed five defined regions on
chromosome 6, ranging from 19.4 to 31.9 Mb, that varied
between 1N and 3N in copy number. Comparisons between the
cell lines and the control population showed additional variations
in these patterns. For example, the 468GFP/YRI comparison
showed an apparent proximal 6q (q12–q24) aneuploidy (3N) along
with an apparent loss of one copy of 6q24-qter. A different profile
was seen with the 468LN/YRI comparison of chromosome 6,
where we observed increased ploidy (up to 5N) that was limited to
the 6q centromeric region. Comparing these data with karyotype
analysis from our previous paper showed that the 468LN line
possesses a population of cells having chromosome 6 variants,
including a common der(6;7)(q13;q22) translocation [1]. Thus, the
468LN vs 468GFP copy number profiles generated by our
analyses represent the cumulative set of chromosomal losses and
gains amassed during the evolution of these cell lines, with these
changes reflecting the retention, the loss and/or the gain of specific
cell clones within the cell line population.
Multi-Array Analyses Define Gene Subsets Related by
Expression, Methylation and Copy Number
We next assessed the functional significance of these complex
rearrangements and copy number changes in the context of gene
expression and epigenetic (DNA methylation) profiles. Gene
expression and promoter methylation patterns were determined
using Affymetrix HGU133_Plus_2 arrays and Human Promoter
1.0R arrays respectively, and two approaches were taken to cross-
reference these data sets. (Expression microarray data are
presented in Tables S4 and S5; methylation microarray data
are published in [4].) First, we used Partek Genomic Suite to
directly align these three data sets in the context of each
chromosome. Using chromosome 6 again as an example
(Figure 5), we compared the 468LN and 468GFP profiles and
observed direct correlations betweenthe regionalblocks related to
copy number (Figure 4) and apparent ‘blocks’ of DNA
methylation along the chromosome. Interestingly, we observed
that a relative loss in copy number correlated with a gain in
hypermethylation, while increases in copy number correlated
with losses in DNA methylation (see 6q in Figure 5). Expression
data for individual genes on the whole do not appear to
consistently correlate with these apparent regional changes in
copy number and DNA methylation. Similar multi-array
Epigenetics and Metastasis
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Figure S1.
Our second approach involved importing probe set IDs from
each of the three microarray platforms and comparing these sets
using the Genespring Venn Analysis tool. Figure 6 shows cross-
referenced probe sets that were hypermethylated, decreased in
expression, and decreased in copy number (Figure 6A) as well as
probe sets that were hypomethylated, increased in expression and
with a gain in copy number (Figure 6B). While platform-specific
gene sets ranged from 1400 to 5700 genes, these Venn diagram
analyses allowed us to identify specific gene subsets (38 to 228
genes; regions 1,2,3,4 in Figure 6) with specific relationships
between expression, methylation status and copy number. As
shown in Figure 6A, region (1) defined 177 genes with a
functional relationship between hypermethylation and decreased
expression that is independent of copy number, while region (2)
defined 228 genes with a functional relationship between
hypermethylation and decreased expression that is dependent
of copy number. Similar gene sets identified in relation to gene
expression and hypomethylation (regions 3,4) are shown in
Figure 6b. (Complete gene lists for regions 1–4 are presented in
Tables S6–S9.)
Ingenuity Pathways Analysis (IPA) of Differentially
Methylated/Expressed/Copy Number Variant Gene
Targets
Annotated gene lists were created with the 405 significantly
hypermethylated (P,0.05; Tables S6, S7) and 246 hypomethy-
lated (P,0.05; Tables S8, S9) gene targets identified within the
four intersected regions that are shown in Figure 6. We used IPA
to investigate the biological relevance of the observed genome-
wide methylation changes by categorizing our data set into
biological functions and/or diseases (Figure 7A). These broad
categories each involved genes having roles in cell death, cell
signalling, cellular movement, cancer and other functional
categories. We also searched the gene lists and identified a
number of significant canonical pathways from the IPA library,
including pathways involved in B cell receptor, p53 and 14-3-3
signalling pathways (Figure 7B). Network analysis was also
performed to provide a graphical representation of gene having
known biological relationships. The top five networks were related
to the EGFR, TGFb1, NFkb, ERK and the Mapk genes, with
each network involving 30–40 hypermethylation/downregulation
and hypomethylation/upregulation events (Figure 8; A,C). We
Figure 1. Experimental design for gene expression, promoter methylation and copy number analysis, and data integration.
Individual microarrays in replicates (red, light blue or gray boxes for expression, promoter methylation, or copy number variation analysis
respectively) were imported into Partek Genomics Suite (PGS) software and background corrected using the RMA algorithm. Genes significantly
altered in expression, promoter methylation, or in copy number were then compared using Venn analysis in PGS, and further validated. GFP: MDA-
MB-468GFP cells; LN: MDA-MB-468GFP-LN cells; RMA: Robust Multichip Averaging.
doi:10.1371/journal.pone.0008665.g001
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and 3) that displayed genes that were independent of copy number
(Figure 8; B,D) and compared these results with the ‘complete’
networks derived from genes in all four regions. The level of
expression of a number of genes in these networks (e.g the EGFR
and Mapk networks; Figure 8, arrows), were predicted to be
dependent on copy number as shown by the green (downregulat-
ed) and red (upregulated) shading of these gene icons in the
networks.
Confirmation of DNA Methylation, Expression and Copy
Number Status
We undertook sodium bisulfite analysis (Figure 9) to confirm the
DNA methylation status at several gene loci putatively identified as
being differentially methylated. Three of these genes (SFN,
TMEM16A and WNT5A) showed dramatic hypermethylation
in the 468LN cells (up to 92% CpG methylation), in contrast with
,1% CpG methylation of the same promoter regions in the
468GFP cells, confirming the promoter microarray in silico
analyses. In contrast, DLC1 and HOXD13 were markedly
hypomethylated in the 468LN cells, in comparison with the
468GFP cells (,1% versus 38–73% methylation). Subsequent
qRT-PCR experiments (Figure 10A) showed that expression of the
hypermethylated SFN, TMEM16A and WNT5A genes was
decreased in 468LN cells, whereas the hypomethylated DLC1
and HOXD13 genes were significantly increased relative to the
468GFP cells. VANGL1 expression did not change. In addition,
we have previously shown that EGFR was significantly hyper-
methylated in 468LN cells (47% vs ,1%) [1].
Copy number status for these genes as determined by SNP6.0
arrays was confirmed by qRT-PCR, using normal human
genomic DNA as an external standard. After normalization to
the internal standard (b-globin), a student’s t-test was used to
compare the copy number of each gene in 468LN cells vs that in
468GFP cells. The results are summarized in Figure 10B. These
experiments showed that as predicted, copy number of SFN,
WNT5A and TMEM16A in 468LN cells (subregion 1; Figure 6)
did not significantly differ from that in 468GFP (p-value 0.33,
0.65, and 0.57, respectively). Similar results regarding similar copy
number were confirmed for DLC1 and HOXD13 (subregion 3,
Figure 6; p value=0.66 and 0.57, respectively). TCF12 increased
in copy number (2.8 fold; p,0.03). In contrast, EGFR (subregion
2, Figure 6) copy number was significantly decreased in LN vs
GFP cells (p=0.001).
Reversal of DNA Methylation Status
Finally, we asked whether the altered methylation patterns seen
in the 468LN cells could be reversed through the use of ‘epigenetic
drugs’ that can restore the normal epigenetic patterns (and
expression patterns) of these genes. 468LN cells were cultured for
72 hours in the presence of 10 mM 5-aza-29-deoxycytidine (5-
azaC) followed by an additional 16h exposure to the histone
deacetylase inhibitor Trichostatin A (TSA; 50 nM). We observed
phenotypic changes in the treated 468LN cells in that they
changed from a mesenchymal to a more epithelial phenotype that
Figure 2. Mapping of genomic DNA copy number variation to individual chromosomes. The thicker vertical bar in the centre of each scan
represent the normal diploid number, and the points represent smoothed averages of the probes on the array. Points falling to the right (or left) of
the bar indicate regions of copy number gain (or loss, respectively) in 468LN vs 468GFP cells.
doi:10.1371/journal.pone.0008665.g002
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PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8665Figure 3. Chromosomal mapping of regions of copy number alteration. Regions appearing increased in copy number are shown in red, and
those decreasing in copy number in blue. A: 468GFP samples vs reference Yoruba population (YRI), B: 468LN samples vs YRI reference population and
C: 468LN vs 468GFP.
doi:10.1371/journal.pone.0008665.g003
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Figure 11A–C). Furthermore, expression analysis using RT-PCR
showed that 5-azaC in both the presence (or absence) of TSA
could re-initiate expression of the stratifin (SFN) gene, which we
had shown was down regulated epigenetically in the 468LN cells
(Figures 9, 10A). As well, TMEM16A expression was re-initiated
after exposure to 5-azaC+TSA while WNT5A trended toward re-
expression relative to control cells. These results confirm that
DNA methylation changes identified from multi-array technology
may be used to identify genes that are potential targets for
epigenetic therapy.
Discussion
Whole genome scanning technologies are providing new
opportunities to identify gene profiles related to breast cancer
progression. While a number of studies have generated genetic
signatures of metastasis risk [7,26], recurrence and clinical
outcome [5,27] and have identified candidates for targeted
therapy [9,10,28], the epigenetic profiles in normal or cancer
cells and in tumours are less well characterized [4,29]. Such
epigenetic signatures encompass the heritable modifications that
do not change the DNA sequence but rather provide ‘extra’ layers
of control that regulate chromatin organization and gene
expression [30,31]. As well, new targeted epigenetic therapies
can potentially be developed to identify and correct epigenetic
alterations and restore normal gene expression patterns that are
dependent on their epigenetic (i.e. DNA methylation) signature
[32,33].
The advent of these various whole genome platforms allows new
opportunities to cross-reference these vast data sets to better
understand tumour progression. Several groups have addressed
allelic imbalance in tumourigenesis and undertaken comparative
studies to integrate copy number analysis with gene expression
patterns in the context of breast [34], lymphoma [35] and
glioblastoma [36,37]. Only a few reports have integrated global
cancer-related changes in DNA methylation, genomic imbalance
and gene expression, most notably in the context of osteosarcoma
[17] and in the development of the SIGMA cancer genome
database [38].
In this present report we address the relationship between
multiple genomic parameters associated with breast cancer
metastasis and progression, by hypothesizing that the complex
chromosomal alterations in cancer cells may complicate the
interpretation of the promoter-specific methylation events respon-
sible for gene-specific expression changes. Our multi-platform
microarray approach simultaneously cross-referenced data sets
related to gene copy number, epigenetic (DNA methylation) and
gene expression patterns in a paired set of MDA-MB-468 breast
adenocarcinoma-derived cell lines that provided a model for
tumour progression. While other reports have combined various
platforms to integrate analysis of high-resolution microarray
Table 1. Association of significantly altered chromosomal regions with copy number variations.
Copy Number Increase Copy number decrease
region size (bases) CNV (LN vs GFP) region size (bases) CNV (LN vs GFP)
Chromosome Median range Median range Median range Median range
1 581135 1567–9179039 5.8 4.1–14.3 448766 178–4767825 1.4 0.1–1.4
2 19747 651–1754927 4.7 2.7–10.7 852822 142214–1328049 1.4 1.0–1.5
3 1714572 537–28619174 4.7 2.9–19.2 127 NA 0.7 NA
4 8158 366–870275 7.7 2.8–20.1 5060 115–54438 0.5 0.1–1.8
5 341544 382–12325442 3.8 3.2–45.9 820233 522–3962771 1.4 0.1–1.5
6 1345260 3648–4638195 2.9 2.4–3.3 3448507 582–31365262 1.2 0.3–1.4
7 1204223 357–10771567 3.8 2.1–47.5 120894 1198–13880419 0.5 0.1–1.8
8 523419 8–36364716 3.5 2.1–43.6 93012 927–416995 1.4 0.2–1.7
9 263469 41754–1489090 3.6 2.4–13.1 128738 6–20341142 1.0 0.2–1.4
10 1276318 565–18668517 3.5 3.0–6.5 179326 202–4999305 1.4 0.1–1.5
11 318665 4142–4710428 3.2 2.4–13.4 28250 13–15453067 0.7 0.2–1.5
12 257993 5211–4882198 3.6 3.3–19.4 15679 33–191249 0.5 0.1–0.9
13 24321 492–2742074 9.9 4.1–14.6 75230 362–18599472 1.1 0.2–1.3
14 158006 945–14212298 3.1 2.9–29.6 14272 210–3791211 0.3 0.1–1.2
15 1169715 382–20624312 3.8 3.1–39.1 139 NA 0.3 NA
16 433423 35–14073681 5.0 2.7–20.0 2976128 16026–15420894 1.2 0.6–1.3
17 496178 335–7515169 4.1 2.8–22.3 692738 820–11936223 1.2 0.2–1.3
18 7296 1105–47923 8.1 5.6–21.9 5199602 255–15390865 1.3 0.9–1.4
19 9639422 NA 3.2 NA 704502 4741–3695496 1.4 0.2–1.5
20 515523 1816–20739653 3.7 3.3–5.3 148965 40585–514274 1.3 1.0–1.9
21 201578 NA 3.3 NA 59842 11145–4587497 0.5 0.3–1.1
22 421267 6473–7039940 3.7 3.1–16.8 214143 7038–943379 1.3 1.1–1.5
X 1766175 413–14118291 4.0 3.0–9.9 123480 253–5781886 1.4 0.1–1.9
doi:10.1371/journal.pone.0008665.t001
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PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8665Figure 4. Chromosomal mapping of copy number variations detected in Human SNP 6.0 arrays. As a reference population, we used a
subset (60 Yoruba females; YRI) of the 270 samples from the International HapMap Project [52] run on the Affymetrix Human SNP 6.0 array [48]. Copy
numbers were normalized to 2 for ease of comparison. Chromosomal locations of regions of significant copy number alteration are shown: 468GFP vs
the Yoruba reference population, 468LN vs Yoruba, and 468LN vs 468GFP.
doi:10.1371/journal.pone.0008665.g004
Figure 5. Representative multi-array alignment of data from the SNP/copy number variation (top), gene expression (middle) and
promoter methylation (bottom) are shown for chromosome 6. In the upper panel 1 indicates relative copy number for 468GFP:468LN. For
the U133 array data, plus represents significantly upregulated genes, and minus represents downregulated genes. For the promoter array data, plus
represents significant regions of hypermethylation, and minus represents hypomethylated regions. Also, the promoter array data is presented on a
log2 scale, while for expression data, the height of the bars representing individual genes is proportional to the expression fold change. Similar multi-
array data specific for all other chromosomes are provided in Figure S1.
doi:10.1371/journal.pone.0008665.g005
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PLoS ONE | www.plosone.org 9 January 2010 | Volume 5 | Issue 1 | e8665Figure 6. Proportional Venn analysis of significantly changed gene regions as determined by multiarray analyses. A: Venn analysis of
genes predicted to be hypermethylated, decreased in expression, and showing a loss in copy number; specific regions of functional overlap are
indicated (1 or 2). B: Venn analysis of genes predicted to be hypomethylated, increased in expression, and showing a gain in copy number; specific




PLoS ONE | www.plosone.org 10 January 2010 | Volume 5 | Issue 1 | e8665profiles [17,38], we used platforms that share the common
Affymetrix technology base. This permitted a robustness of design
and economy that allowed standardized bioinformatic assessment
and cross-referencing of the data sets, using a single software
bioinformatics package (Partek Genomic Suite) to import, analyze
and cross-reference raw data from the various microarray
platforms.
Our initial copy number analyses revealed complex chromo-
somal rearrangements with approximately 96 large regions of
chromosome copy number differences in the 468LN versus the
468GFP cells, ranging up to 100 megabases (Figure 2). While some
of these chromosomal changes appeared to reflect the common
aberrations we previously reported by karyotype analysis [1],
direct comparisons cannot easily be made, since karyotype
analyses are described as the frequency of chromosomal changes
on a cell to cell basis, while microarray data are generated from
the mixture of DNAs from the multiple cell clones that populate
the cell line. Hence, validation of individual gene targets is
essential to confirm their functional relevance to the cancer cell
phenotype. Since normal cells were not available from the original
host patient from whom the cell lines were derived, we performed
in silico comparisons with a reference population generated by the
International HapMap project (Figure 4). These analyses identi-
fied additional differences between the cell lines and the normal
population and allowed us to better relate the significance of these
chromosomal changes to variable DNA methylation patterns, as
described below.
The multi-array comparisons that were undertaken involved the
complementary approaches of direct alignment of the data sets in
the context of each chromosome (Figure 5A and Figure S1), as well
as comparison of the data sets using the Genespring Venn Analysis
tool (Figure 6). It was immediately apparent from our chromo-
some-based analyses that there were direct correlations between
regional blocks related to copy number and apparent ‘blocks’ of
DNA methylation along each of the chromosomes. Many of the
relative losses in copy number correlated with an apparent gain in
hypermethylation, while increases in copy number tended to
correlate with losses in DNA methylation, again in the 468LN cells
compared to the parental 468GFP line. These data are supportive
of previous reports describing lower levels of DNA methylation in
tumours relative to control DNA [39], with this loss of methylation
mainly due to hypomethylation of repetitive DNA sequences and
demethylation of coding regions and introns [40]. Furthermore,
levels of genomic DNA hypomethylation increase as the cancer
progresses from a benign proliferation of cells to an invasive cancer
[41], which may explain some of the regional methylation
differences we observe in the 468LN cells. Comparisons between
cell line DNAs and the normal reference DNA provide further
interpretation of the ‘additive’ nature of these copy number
changes and their relationship to DNA methylation. As shown in
Figure 7. Ingenuity Pathway analyses. A: Top functional categories and B: canonical pathways from our data set based on significance.
doi:10.1371/journal.pone.0008665.g007
Epigenetics and Metastasis
PLoS ONE | www.plosone.org 11 January 2010 | Volume 5 | Issue 1 | e8665Figure 12, the additive copy number differences we observed can
be considered relative to specific changes in each of the cell lines
relative to normal cells and points to the progressive nature of
these genomic changes (Normal.468GFP.468LN), some of
which contribute to gene expression losses and gains mediated
through aberrant DNA methylation events (for example, the loss
of a 7p isochromosome present in 468GFP cells and absent in the
derived 478LN cells [1].
Figure 8. Network analysis was performed to provide a graphical representation of genes having known biological relationships.
The EGFR and Mapk networks presented are shown in duplicate, with (A and C), displaying genes comprising the four insecting subregions shown in
Figure 6 (regions 1,2,3 and 4) and (B and D) displaying genes comprising the two intersecting subregions (regions 1 and 3) that have a methylation/
expression status that is independent of copy number. Green icons indicate downregulated genes and red indicates upregulated genes. The arrows
indicate selected genes that have a variable methylation status that is dependent on copy number status.
doi:10.1371/journal.pone.0008665.g008
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(Figure 6) provided the next level of analysis to sort and prioritize
functionally relevant genes in this model system. Our integrative
approach allowed us to refine the epigenetic signature that
encompassed 2792 hyper- and 1478 hypomethylated events down
to ,650 variably-methylated gene promoter regions. Ingenuity
Pathway Analysis further categorized our data set into functional
categories and networks (Figure 7) from which high priority gene
targets could be validated for their DNA methylation, expression
and copy number status. The methylation and expression status of
five of these targets is shown in Figures 9 and 10A, confirming the
prediction of hypermethylation (and decreased expression) of SFN,
TMEM16A and WNT5A and the hypomethylation (and
increased expression) of DLC1 and HOXD13 in the 468LN cells.
Furthermore, we used qRT-PCR to confirm that these correla-
tions between the methylation and gene expression status of these
genes was independent of copy number, as predicted by the
assignment of these genes to Venn subregions 1 (SFN,
TMEM16A, WNT5A) and 3 (DLC1, HOXD13) as shown in
Figure 6.
Finally, we addressed the utility of microarray technologies to
identify potential targets for epigenetic-based therapies to restore
normal gene expression patterns. The stratifin gene (SFN), which
has a hypermethylated promoter and displays minimal expression
in the 468LN cells, was chosen as the target gene for these
experiments using the demethylating agent 5-azaC and the histone
deacetylase inhibitor TSA [42]. Stratifin (14-3-3s) is a member of
the 14-3-3 gene family that regulates numerous cell pathways
relevant to breast and prostate cancer including cell cycle arrest,
signal transduction, apoptosis and proliferation [43,44,45]. We
identified stratifin in our experiments through its relationship with
genes focussed in the ras/Mapk pathway identified by Ingenuity
Pathway Analysis (Figure 8), and we subsequently confirmed its
hypermethylated status and loss of expression in 468LN cells
(Figure 9, 10A). We observed phenotypic changes in the 5-azaC/
TSA treated 468LN cells in that they changed from a
mesenchymal to a more epithelial phenotype that was more
similar to the parental 468GFP cell line (Figure 11A–C).
Furthermore, expression analysis using RT-PCR showed that 5-
azaC, in both the presence and absence of TSA, could re-initiate
expression of SFN while TMEM16a was re-expressed significantly
only after the exposure to both drugs. Our data suggest that
epigenetic changes cross-referenced with other multi-array whole
genome technologies can identify genes as potential targets for
epigenetic therapy in the context of multiple genomic character-
istics (gene copy number, DNA methylation and expression), and
would likely provide more accurate prognostic and predictive
assessment than assessing single genes, or single platforms alone
[46], particularly when these changes are cross-referenced with
patient tumour material.
Our multi-platform approach refines the epigenetic signatures in
breast cancer metastasis in the context of gene-specific functional
changes in gene expression and copy number. As well, we show that
this approach that cross-references multiple whole-genome data
sets, also can isolate and identify targets that are altered by copy
number (but are not epigenetically modified) and more precisely
map functionally important epigenetic signatures associated with
cancer progression. Our approach provides enhanced opportuni-
ties, particularly in the context of patient tumour material, to
identify therapeutic targets for breast cancer treatment that are
epigenetically regulated by alterations in DNA methylation.
Supporting Information
Figure S1 Multi-platform integrative analysis of copy number,
expression, and promoter array data.
Found at: doi:10.1371/journal.pone.0008665.s001 (2.06 MB
PDF)
Figure 9. Sodium bisulfite sequencing, gene expression and copy number. Sodium bisulfite sequencing of representative genes detected
with aberrant methylation with (or without) a concomitant change in copy number. Each square represents a CpG (open square: unmethylated;
closed square: methylated). Each row of squares one cloned PCR sequence across the gene promoter (5–20 clones were sequenced per gene).
Percentages indicate degree of methylation at each gene locus.
doi:10.1371/journal.pone.0008665.g009
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PLoS ONE | www.plosone.org 13 January 2010 | Volume 5 | Issue 1 | e8665Table S1 PCR Primer List.
Found at: doi:10.1371/journal.pone.0008665.s002 (0.03 MB
PDF)
Table S2 Regions showing an increase in copy number, (468LN
relative to 468GFP). Included are associated genes contained
within the regions.
Found at: doi:10.1371/journal.pone.0008665.s003 (0.07 MB
PDF)
Table S3 Regions showing a decrease in copy number, (468LN
relative to 468GFP). Included are associated genes contained
within the regions.
Found at: doi:10.1371/journal.pone.0008665.s004 (0.05 MB
PDF)
Table S4 Genes significantly increased in expression, 468LN vs
468GFP. Expression microarray (HGU133 Plus_2) data were
prefiltered to remove genes changing less than 2 fold, and an
Figure 10. Expression and copy number analyses. A: Quantitative real time RT-PCR expression data for each of these genes, including EGFR.
Scale of the y-axis is log10 of the fold change. B: Determination of copy number by quantitative real time PCR (qRT-PCR). Primers spanning an exon of
the gene of interest were designed using ExonPrimer software, and qRT-PCR performed using 15 ng genomic DNA from 3 biological replicates each
of LN and GFP DNA as template. Shown is the LN/GFP ratio, 6 standard error of the mean (SEM). Data were normalized to b-globin as a reference
gene. A p-value ,0.05 indicates that mean normalized LN copy numbers in LN triplicates were significantly different from those in GFP.
doi:10.1371/journal.pone.0008665.g010
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multiple testing correction using the algorithm of Benjamini and
Hochberg was used to reduce the false discovery rate.
Found at: doi:10.1371/journal.pone.0008665.s005 (0.46 MB
PDF)
Table S5 Genes significantly decreased in expression, 468LN
vs 468GFP. Expression microarray (HGU133 Plus_2) data were
prefiltered to remove genes changing less than 2 fold, and an
ANOVA was run to determine significant (p,0.05) changers. A
multiple testing correction using the algorithm of Benjamini
and Hochberg was used to reduce the false discovery
rate.
Found at: doi:10.1371/journal.pone.0008665.s006 (0.51 MB
PDF)
Table S6 Genes Hypermethylated AND Decreased in expres-
sion, no change in copy number (Venn region 1).
Found at: doi:10.1371/journal.pone.0008665.s007 (0.05 MB
PDF)
Table S7 Genes Hypermethylated AND Decreased in expres-
sion, loss in copy number (Venn region 2).
Found at: doi:10.1371/journal.pone.0008665.s008 (0.07 MB
PDF)
Table S8 Genes Hypomethylated AND Increased in expression,
no change in copy number (Venn region 3).
Found at: doi:10.1371/journal.pone.0008665.s009 (0.06 MB
PDF)
Table S9 Genes Hypomethylated AND Increased in expression,
gain in copy number (Venn region 4).
Found at: doi:10.1371/journal.pone.0008665.s010 (0.07 MB
PDF)
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Figure 11. Exposure to 5-aza-2-deoxycytidine and Trichostatin A. A–C: 468LN cells were cultured for 7 days in A: the absence or B: the
presence of 5-aza-2-deoxycytidine followed by C: an additional 16 h exposure to the histone deacetylase inhibitor Trichostatin A (TSA). D: Induction
of epigenetically down-regulated genes. 468LN cells were cultured in the absence (Control) or presence of 5-aza-2-deoxycytidine (5AZA) for 72 hours
(5AZA 72 hr), 88 hours (5AZA 88 hr), or for 72 hours followed by the addition of Trichostatin A (TSA) for 16 hours (5AZA+TSA). Total RNA was
extracted and qRT-PCR performed as described in the text. Significant group differences were determined using ANOVA followed by the Student-
Newman-Keuls multiple comparison procedure. a: significantly different (p,0.05) vs Control. b: significantly different vs 5AZA 72 hr. c: significantly
different (p,0.05) vs 5AZA 88 hr.
doi:10.1371/journal.pone.0008665.g011
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